Pantoprazole
- Generic Name
- Pantoprazole
- Brand Names
- Protonix, Somac Control, Tecta, Pantozol Control, Controloc Control
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15F2N3O4S
- CAS Number
- 102625-70-7
- Unique Ingredient Identifier
- D8TST4O562
- Background
Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be...
- Indication
Pantoprazole Injection:
Treatment of gastroesophageal reflux disease associated with a history of erosive esophagitis
...
- Associated Conditions
- Erosive Esophagitis, GERD With Erosive Esophagitis, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Helicobacter Pylori Infection, Stress Ulcers, Zollinger-Ellison Syndrome, Conditions where a reduction of gastric acid secretion is required, Pathological hypersecretory conditions
- Associated Therapies
- -
Efficacy of Pantoprazole in Patients Older Than 12 Years Who Have Symptoms of Non-Erosive Reflux Disease (NERD) or Erosive Gastroesophageal Reflux Disease (eGERD)
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2012-05-08
- Lead Sponsor
- Nycomed
- Target Recruit Count
- 1995
- Registration Number
- NCT00561730
- Locations
- 🇩🇪
Nycomed Deutschland GmbH, Zwickau, Germany
Efficacy of Pantoprazole in Patients Older Than 12 Years With Reflux Associated Sleep Disorders (PULS)
- Conditions
- Interventions
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2012-05-08
- Lead Sponsor
- Nycomed
- Target Recruit Count
- 8616
- Registration Number
- NCT00562094
- Locations
- 🇩🇪
Nycomed Deutschland GmbH, Überlingen, Germany
The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms (BY1023/NL511)
- Conditions
- Interventions
- First Posted Date
- 2007-03-21
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 40
- Registration Number
- NCT00449813
- Locations
- 🇨🇭
Altana Pharma/Nycomed, Zürich, Switzerland
Study Comparing 2 Different Formulations of Pantoprazole in Healthy Adults.
- Conditions
- First Posted Date
- 2006-10-04
- Last Posted Date
- 2007-03-08
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Registration Number
- NCT00383916
High Versus Standard Dose of Proton Pump Inhibitors (PPIs) in Peptic Ulcer Bleeding
- Conditions
- First Posted Date
- 2006-09-08
- Last Posted Date
- 2007-04-05
- Lead Sponsor
- Casa Sollievo della Sofferenza IRCCS
- Target Recruit Count
- 450
- Registration Number
- NCT00374101
- Locations
- 🇮🇹
Division of Internal Medicine, Polla, Salerno, Italy
🇮🇹Division of Gastroenterology, Vasto, Italy
🇮🇹DIvision of Gastroenterology, Como, Italy
Study Evaluating Pantoprazole in Adolescents With GERD
- Conditions
- First Posted Date
- 2006-08-23
- Last Posted Date
- 2007-12-10
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT00367614
Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)
- First Posted Date
- 2006-08-17
- Last Posted Date
- 2010-05-04
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 129
- Registration Number
- NCT00365300
Study Evaluating Pantoprazole in Neonates and Preterm Infants With GERD
- First Posted Date
- 2006-08-10
- Last Posted Date
- 2010-05-14
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 59
- Registration Number
- NCT00362609
Symptom Assessment in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) or enGERD (Endoscopic-negative GERD) After Treatment With Pantoprazole (BY1023/M3-343)
- First Posted Date
- 2006-06-13
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 628
- Registration Number
- NCT00336219
- Locations
- 🇭🇺
Altana Pharma/Nycomed, Vác, Hungary
Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Non-erosive Reflux or Gastroesophageal Reflux Disease (BY1023/DE-004)
- First Posted Date
- 2006-05-16
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- Nycomed
- Target Recruit Count
- 29
- Registration Number
- NCT00326027
- Locations
- 🇩🇪
Nycomed Deutschland GmbH, Wiesbaden, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.